Matching a drug to a patient’s biology is not a new idea, but it hasn’t caught on in neuropsychiatric disorders, which have high failure rates in drug studies. The technology of Alto Neuroscience ...

Alto Ingredients, Inc. (NASDAQ:ALTO) just released its latest second-quarter report and things are not looking great. Revenues missed expectations somewhat, coming in at US$218m, but statutory ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

Alto Ingredients, Inc. continues to erode shareholder value, hitting new lows despite cost-saving initiatives. ALTO's financials show a $55 million decline in shareholder equity in 2024 along with ...